Oligonucleotide (siRNA) · Gene silencing: LPA mRNA (LPA) · developed by Silence Therapeutics
Zerlasiran (SLN360) is a double-stranded small interfering RNA that targets LPA messenger RNA, reducing production of the apolipoprotein(a) component of lipoprotein(a). It is being studied in elevated lipoprotein(a), hyperlipidemias, dyslipidemias, and cardiovascular diseases including atherosclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05537571 | Phase 2 | Cardiovascular Diseases | Completed | SLN |
| NCT04606602 | Phase 1 | Hyperlipidemias | Completed | MEDP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AtherosclerosisCardiovascular DiseasesDyslipidemiasElevated Lp(a)HyperlipidemiasLipoprotein(a)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SLN page.
See SLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLN catalysts and pipeline →